logo
Plus   Neg
Share
Email

EU Approves Roche's Perjeta To Treat Metastatic Breast Cancer

Roche announced that it has received approval from European regulators for its perjeta drug to help treat breast cancer.

The approval comes from the European Medicines Agency and covers patients with previously untreated HER2-positive metastatic breast cancer. The drug is approved in combination with two other treatments - Herceptin and docetaxel - in adult patients who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

The European approval comes after a late-stage trial showed that the combination of perjeta, Herceptin and chemotherapy provided patients with a median of 6.1 months longer without their disease worsening. It also provided a 34 percent reduction in the risk of death compared to Herceptin and chemotherapy alone.

The company said that perjeta is now approved in the EU, the U.S., and Switzerland for the treatment of people with this form of breast cancer. Further country approvals are anticipated during 2013.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Member of Congress have reportedly been told President Donald Trump's administration has reached an agreement to put Chinese telecom giant ZTE Corp. back in business. Reports from the New York Times and Reuters said the deal brokered by the Commerce Department would require ZTE to pay a substantial... Delta Air Lines will resume non-stop flights between the U.S. and India next year, almost a decade after it exited the Indian market. The airline said Thursday that its decision to resume non-stop flights from the U.S. to India follows agreements between the U.S. and the governments of the United Arab Emirates and Qatar to address the issue of government subsidies provided to state-owned carriers. Mortgage rates continued their upward trend this week and hit a seven-year high, even as housing demand remained robust. According to data released Thursday by mortgage finance provider Freddie Mac, the 30-year fixed-rate mortgage rose to 4.66 percent in the week ending May 24, from 4.61 percent in the prior week and 3.95 percent a year ago. This is also the highest level since May 5, 2011.
Follow RTT